- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Biopsy visualization unit gets nod
Ultrasound peripheral developer EchoCath received Food and DrugAdministration 510(k) approval in September for its ColorMarkdevice for improving needle visualization during ultrasound-guidedbiopsy. The device consists of a vibrating clip attached to a
Ultrasound peripheral developer EchoCath received Food and DrugAdministration 510(k) approval in September for its ColorMarkdevice for improving needle visualization during ultrasound-guidedbiopsy.
The device consists of a vibrating clip attached to a biopsyneedle. The vibration creates a phase shift that shows up as amultihued stripe on color-flow Doppler scanners. EchoCath unveiledthe technology at the American Institute of Ultrasound in Medicinemeeting in March (SCAN 5/19/93).
ColorMark could aid the transition of biopsy procedures fromCT to ultrasound, as well as increase the accuracy of fine-needleaspiration biopsy, the manufacturer said. EchoCath is developinga ColorMark system for the Bard biopsy gun.
The firm is gearing up production of ColorMark devices andintends to begin shipping product in the first quarter of nextyear.
BRIEFLY NOTED:
- President Clinton formally introduced health-care reformlegislation in Congress last week. In introducing the package,Clinton urged Congress to pass health-care reform by the end ofnext year. Copies of the plan, as well as an executive summaryof the proposal, are available for $45 by contacting the GovernmentPrinting Office at 202/783-3238.
MRI Long Covid Study Reveals Link Between Lower Pulmonary Gas Exchange and Cognitive Dysfunction
November 26th 2024For patients with Long Covid, lower pulmonary gas exchange may be associated with lower gray and white matter volume, according to new MRI research to be presented at the Radiological Society of North America (RSNA) conference.
New DEXA Scan Study Links Thyroid Medication Levothyroxine to Higher Bone Loss Risk in Seniors
November 25th 2024Use of the medication levothyroxine, commonly prescribed for hypothyroidism, was associated with greater long-term loss of total body bone mass in seniors, according to new DEXA research to be presented at the Radiological Society of North America (RSNA) conference.
